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Abstract
Invasive fungal infections (IFIs) are life-threatening conditions that require rapid diagnostic and optimal management to mitigate their high
morbidity and mortality rate. They are also associated with a high economic burden, owing to prolonged hospitalization, the need for
intensive supportive care, and the consumption of costly new antifungal agents. To address these issues, several international organizations
have proposed guidelines for the management of IFIs. The consistency and reliability of these guidelines have rarely been assessed. This
article is a review of the differences between the recommendations of the Infectious Diseases Society of America, the European Conference
on Infection in Leukaemia, and the European Society of Clinical Microbiology and Infectious Diseases, and will focus on targeted treatment
and diagnostic procedures. Although the conclusions of the three groups of experts are in many points similar we outlined some important
differences in the methodology and conclusions of ESCMID. The use of these guidelines has the potential to enhance the management of
fungal infections but is probably currently suboptimal.
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Introduction
In recent years, invasive fungal infections (IFIs) have emerged as
an important cause of life-threatening infection, especially in the
context of immunosuppression, but also frequently in non-neu-
tropenic patients, mainly in those requiring treatment in an
intensive-care unit. Despite the growing body of evidence and
knowledge in this ﬁeld, the diagnosis and management of these
complex infections remain challenging. International guidelines
based on evidence-based medicine criteria that have been
published in the past decade by three groups (including two
scientiﬁc societies) will be the focus of this article: the European
Society of Clinical Microbiology and Infectious Diseases
(ESCMID) [1–7], the Infectious Diseases Society of America
(IDSA) [8,9], and the European Conference on Infection in
Leukaemia (ECIL) [10–13]. The present review aims to ﬁnd and
analyse the discrepancies in the methodology (Table 1) and
conclusions of these different guidelines for invasive candidiasis,
aspergillosis, and mucormycosis. We will basically focus on
diagnostic procedures and treatment recommendations, and
exclude topics on combination therapies and prophylaxis.
Children and neonates were also considered in guidelines
provided by the ESCMID and the IDSA (partly summarized in
Table 3), but not in those provided by the ECIL, but review of
these would lead to this article exceeding the speciﬁed word
limit. Therefore, the scope of this comparison was voluntarily
restricted, and it is not an exhaustive assessment of each
recommendation throughout the three guidelines.
Methods
The development of guidelines should be a standardized
process, and the methodologies used by the three groups
to develop these recommendations are quite similar.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases
REVIEW 10.1111/1469-0691.12426
TABLE 1. Comparison of the methodology and experts overlap
ECIL ESCMID IDSA
Population Adult haematological malignancies patients and
adult HSCT recipients, adult non-neutropenic
patients (ICU)
Paediatric patients, HIV patients, non-neutropenic
adult patients (ICU), adult haematological malignancies
and cancer patients and adult HSCT and SOT-recipients
Paediatric patients, HIV
patients, non-neutropenic
adult patients (ICU), adult
haematological malignancies
patients and adult HSCT
and SOT-recipients
Scope Diagnosis procedures
Antifungal prophylaxis
Invasive aspergillosis
Invasive Candidiasis
Mucormycosis
Diagnosis procedures
Anti-candida prophylaxis
Invasive candidiasis
Mucormycosis
Antifungal prophylaxis
Invasive, chronic and allergic
forms of aspergillosis
Invasive candidiasis
Experts selection All guidelines
EORTC, EBMT, ELN, ICHS
Candidiasis
EFISG, EBMT, ECCM, EORTC, ESICM
Mucormycosis
EFISG, ECCM
Candidiasis
IDSA, SPGC
Aspergillosis
Methodology not detailed
Evidence search Medline, PubMed, Cochrane Library, Abstracts
of ASH, ICAAC, ASCO, ESCMID and EBMT
(limited to the 4 previous years)
Pubmed Pubmed
Last year covered in search 2009 2011 2009
Methodology and achievement
of experts consensus
Organization committee deﬁnes topic and
main questions
Working groups (3–6 experts) review the
literature and prepare recommendations/updates
Meeting in ECIL with group consensus
EFISG deﬁnes clinical questions, intention of the
recommendations and intervention
Working groups review the literature and prepare
recommendations (note: literature database
available to the whole panel via FTP-server)
2 Meetings in the ESCMID Conference on 2
consecutive years with group consensus
Note: Grading of the SoR and QoE in two
separate evaluation
Presentation in workshop session in ESCMID, and
incorporation of points of discussion
External peer review
Candidiasis guidelines:
Expert panel deﬁnes clinical
questions
All experts review the
literature and contribute
to the preparation of
the recommendation
Deliberations during
11 teleconferences
1 face-to-face meeting
External peer review
Approved by IDSA SPGC
and Board of directors
Aspergillosis guideline:
Methodology not detailled
Expert overlap With ESCMID : 15
With IDSA : 2
With ECIL : 15
With IDSA : 2
With ECIL: 2
With ESCMID: 2
Financial support Experts meetings supported through
educational grants from biomedical and
pharmaceutical companies
ESCMID IDSA
EBMT: European Group for Blood Marrow Transplantation, ECCM: European Confederation of Medical Mycology, EFISG: ESCMID Fungal Infection Study Group, ELN: European
Leukemia Net, EORTC: European Organisation for Research and Treatment of Cancer, ESICM: European Society of Intensive Care Medicine, ICHS: Immunocompromised Host
Society, QoE: quality of evidence, SPGC Standards and Practice Guidelines Committee, SoR: strength of recommendation.
TABLE 2. Presentation of the different grading systems for the strength of recommendation
Strength of
recommendation ECIL until 2009 ESCMID IDSA/ECIL since 2009
A Strong evidence for efﬁcacy and substantial
clinical beneﬁt: strongly recommended
ESCMID strongly supports a
recommendation for use
Good evidence to support a
recommendation for or against use
B Strong or moderate evidence for efﬁcacy,
but only limited clinical beneﬁt: generally recommended
ESCMID moderately supports
a recommendation for use
Moderate evidence to support a
recommendation for or against use
C Insufﬁcient evidence for efﬁcacy, or efﬁcacy does not
outweigh possible adverse consequences (e.g. drug
toxicity or interactions) or cost of chemoprophylaxis
or alternative approaches: optional
ESCMID marginally supports
a recommendation for use
Poor evidence to support a
recommendation
D Moderate evidence against efﬁcacy or for adverse
outcome: generally not recommended
ESCMID supports a
recommendation against use
NA
E Strong evidence against efﬁcacy or for adverse
outcome: never recommended
NA NA
Quality of evidence
I Evidence from at least one well-executed randomized trial
II Evidence from at least one well-designed clinical trial
without randomization; cohort or case-controlled
analytical studies (preferably from more than
one centre; multiple time-series studies; or
dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities
based on clinical experience, descriptive studies,
or reports from expert committees
ECIL, European Conference on Infection in Leukaemia; ESCMID, European Society of Clinical Microbiology and Infectious Diseases; IDSA, Infectious Diseases Society of America;
NA, not applicable.
Added Index proposed by the ESCMID only for level II of evidence: r, meta-analysis or systematic review or randomized controlled trials; t, transferred evidence, i.e. results from
different patient cohorts, or similar immune-status situation; h, comparator group is a historical control; u, uncontrolled trial; a, published abstract (presented at an international
symposium or meeting).
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Nevertheless, there are some differences in term of objectives,
scope, and editorial choices. In particular, it is important to
note that the ECIL group restricted its recommendations to
the group of patients with haematological diseases and to
haematopoietic stem cell transplant (HSCT) recipients. There
are also some important discrepancies in the methodology
regarding the presentation of the strength of the recommen-
dations (SoR) (Table 2). The IDSA uses a three-category
system to rank its recommendations. This system was adopted
by the ECIL group in its 2009 update of its guidelines, replacing
the previous ﬁve-category system in order to harmonize the
different international guidelines. The ESCMID proposed a
four-category system in its recommendations on invasive
candidiasis in 2012 (a further three ESCMID guidelines, which
incorporate this ESCMID system of four categories, are in
development or have been submitted for publication). There is
a difference in the paradigm underlying this system in compar-
ison with the IDSA. The latter mainly serves the purpose of
ranking the quality of evidence (QoE), which leads to the
recommendation’s grade. The ESCMID system, on the other
hand, aims at ranking the strength of the recommendations by
the interpretation of an international expert group, based on
their analysis of the literature. This difference seems minimal,
but leads to very different conclusions in the case of some much
debated issues (e.g. the application of amphotericin B deoxy-
cholate). To further enhance the use of its guidelines in daily
practice, the ESCMID group deﬁnes ‘intention’ for each of its
recommendations (the intervention). According to the GRADE
working group: ‘Recommendations to administer, or not
administer, an intervention,’ should be ‘based on the trade-offs
between beneﬁts on the one hand, and risks, burden and,
potentially, costs on the other.’ If beneﬁts outweigh risks and
burden, experts will recommend that clinicians offer a treat-
ment to typical patients. The uncertainty associated with the
trade-off between the beneﬁts and risks and burdens will
determine the SoR [14]. The ESCMID Candida guidelines
followed this advice for grading a recommendation, as the QoE
by itself is usually not sufﬁcient. All three groups differentiate
only three instead of the four categories proposed by GRADE
to classify the QoE (high, moderate, low, or very low). The
authors of this article think that three categories are sufﬁcient
to provide evidence, as at least the ESCMID QoE provides a
more detailed subcategorization for level II [1].
Candidaemia/invasive candidiasis in haematological patients
and HSCT recipients
The most updated guidelines for Candida infections were
released by the IDSA in 2009 [8], the ECIL in 2011 [10], and
the ESCMID in 2012 [1–6] (Table 3). For candidaemia in patients
with haematological malignancies and HSCT recipients, the
recommendations for ﬁrst-line antifungal therapy are relatively
consistent in the three guidelines, with echinocandins being the
drugs of choice. The ECIL group gives a more moderate
recommendation for the use of these agents, by grading themBII.
Liposomal amphotericin B (LAmB) is recommended as a
ﬁrst-line therapy alternative with the same strength as echino-
candins by the IDSA and the ECIL (respectively, AII and BII).
Owing to its increased toxicity, the ESCMID proposes a weaker
recommendation (BII), despite non-inferiority in comparison
with micafungin. The other lipid formulations of amphotericin B
are not considered in the IDSA guidelines, but the ECIL
recommends their use with the same strength as for liposomal
amphotericin B (BII). Owing to their toxicity proﬁle and weaker
database, the ESCMID proposes these agents for second-line
treatment, with a CII recommendation (marginally supports a
recommendation for use) for amphotericin B lipid complex
(ABLC) and aCIII recommendation for amphotericin B colloidal
dispersion (ABCD). Fluconazole is no longer considered to be a
ﬁrst-line therapy option. The IDSA considers its use to be
possible in patients with mild to moderate disease and no prior
exposure to azoles (BIII), whereas the ESCMID advises that it
should be reserved as a step-down therapy option in case of
infection with susceptible Candida species (CII). One of the main
differences concerns the recommendation on the use of
amphotericin B deoxycholate: the ECIL considers its use as an
option (CIII), unless there is concomitant nephrotoxic medica-
tion (DIII) or renal impairment (EIII); the IDSA does not state a
recommendation; and the ESCMID strongly recommends
against its use in adults, because of its increased toxicity in
comparison with the other, clearly better, therapy options
(DII). There is also a difference in recommendations between
the ESCMID and the two other groups concerning the
follow-up strategy. The ESCMID recommends a switch to an
echinocandin if the patients were receiving ﬂuconazole or
liposomal amphotericin B, e.g. for prophylaxis or empirical
therapy. The IDSA considers it reasonable to pursue the
same treatment if the patients are stable.
The management of central venous catheters in the context
of candidaemia is less straightforward in this population of
patients than in non-neutropenic patients, owing to the
increased morbidity associated with catheter replacement.
The IDSA guidelines only state that removal should be
considered for patients who have persistent candidaemia
(BIII); the ECIL gives a similar recommendation (BIII), unless
Candida parapsilosis is involved, in which case the authors
consider removal to be mandatory (AII), this species being
more frequently associated with catheter-associated infec-
tions. The ESCMID supports more clearly early catheter
removal (AII) if feasible, and the use of echinocandins (or
liposomal amphotericin B) in cases of clinically necessary
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TABLE 3. Comparison of the recommendations on the management of candidaemia/invasive candidiasis
ECIL ESCMID IDSA
Antifungal susceptibility
testing
Recommended by lack of
clinical response A II
Recommended to support a
change in initial therapy B II
Recommended before a switch
to oral azole A II
Recommended for all Candida
strains isolated from blood
and other deep sites (no SoR)
Recommended for superﬁcial isolates in
cases of no-response to treatment
or relapses (no SoR)
Recommended for Candida glabrata (no SoR)
Recommended by failure to respond to initial
antifungal therapy (no SoR)
Recommended if azole resistance is strongly
suspected (no SoR)
Not recommended for Candida albicans
(no SoR)
Therapeutic drug
monitoring
NR Recommended for voriconazole and
posaconazole and 5-FU (no SoR)
Recommended for echinocandins for patients
with extra-corporeal membrane oxygenation
(ECMO) (no SoR)
Recommended for voriconazole and
itraconazole for patients with prolonged
courses for deep-seated or refractory
infections (no SoR)
Diagnosis procedures Blood cultures: always
recommended (no SoR)
Mannan/Anti-mannan:
For candidaemia: C II
For hepatosplenic candidiasis: B III
b-Glucan:
For haematological patients B II
Blood cultures: essential investigation (no SoR)
Mannan/anti-mannan:
For candidaemia: recommended II
For invasive candidiasis: not recommended
(no data)
For hepatosplenic candidiasis: recommended II
b-Glucan:
For candidaemia: recommended II
For invasive candidiasis: recommended II
NR
Initial targeted treatment in
the haematological
malignancies patients and
HSCT-recipients
Caspofungin B II
Micafungin B II
Anidulafungin B II
L-AmB B II
ABLC B II
ABCD B II
Voriconazole B II
Fluconazole C III
AmB-d C IIIa
Itraconazole NR
Posaconazole NR
Caspofungin A IIt
Micafungin A IIt
Anidulafungin B IIt
L-AmB B IIt
Voriconazole C IIt
Fluconazole C IItb
ABLC C IIa
ABCD C III
AmB-d D IIt
Itraconazole D III
Posaconazole D III
Caspofungin A II
Micafungin A II
L-AmB A II
Anidulafungin A III
Fluconazole B IIc
AmB-d NR
ABLC NR
ABCD NR
Itraconazole NR
Posaconazole NR
Voriconazole NR
Initial targeted treatment in
non-neutropenic patients
Caspofungin A I
Anidulafungin A I
Micafungin A I
L-AmB A I
AmB-d A Ia
Fluconazole A Id
Voriconazole A Ie
ABLC A II
ABCD A II
Itraconazole NR
Posaconazole NR
Caspofungin A I
Anidulafungin A I
Micafungin A I
L-AmB B I
Voriconazole B If
Fluconazole C If,g
ABLC C IIa
AmB-d D I
ABCD D IIa
Itraconazole D IIa
Posaconazole D III
Caspofungin A I
Anidulafungin A I
Micafungin A I
L-AmB A Ih
AmB-d A I
Fluconazole A Ii
Voriconazole A I
Itraconazole NR
Posaconazole NR
ABLC NR
ABCD NR
Initial targeted treatment in
neonates
NR AmB-d 1 mg/kg/day B II
L-AmB 2.5–7 mg/kg/day B II
Fluconazole 12 mg/kg/day B II
Micafungin 4–10 mg/kg/day B II
Caspofungin 25 mg/m²/day C II
ABLC C II
AmB-d &mg/kg/day A II
L-AmB 3–5 mg/kg/day B II
Fluconazole 12 mg/kg/day B II
Echinocandins B III
ABLC NR
Combination therapy NR AmB-d + ﬂuconazole D I
AmB-d + 5-Fu D II
Efungumab + lipid-associated amphotericin B D
II
NR
Intravenous catheter
removal
Non-haematological patients A II
Haematological patients B III
Candida parapsilosis infection A II
Non-neutropenic patients A IIr
Haematological patients A IIu
Non-neutropenic patients A II
Neutropenic patients: B III
Treatment duration Follow up blood cultures: NR
Non-neutropenic: 14 days after the last
positive blood culture and resolution
of signs and symptoms B III
Neutropenic patients: 14 days after
the last positive blood culture and
resolution of signs and symptoms and
resolution of neutropenia C III
Take at least one blood culture per day until
negative B III
Non-neutropenic patients: treat 14 days after
the end of candidaemia B II
Neutropenic patients: treat at least 14 days
after last positive blood culture, if neutropenia
persist appropriate duration not deﬁned
(no SoR)
Blood cultures should be performed daily or
every other day (no SoR)
Non-neutropenic 14 days after clearance of
Candida from the bloodstream A III
Neutropenic patients: 14 days after clearance
of Candida from the bloodstream and
resolution of the neutropenia (no SoR)
Follow up Importance of an active search for
dissemination of infection in leukemic
patients following neutrophil recovery
(ocular fundus + abdominal imaging)
(no SoR)
Step down therapy: NR
Transoesophageal echocardiography B IIa
Fundoscopy B II
If CVC, PICC or intravascular devices, search
for thrombus B III
Step-down to ﬂuconazole after echinocandin
after 10 days of IV, if species is susceptible,
patient tolerates PO and patient is stable B II
Fundoscopy (no SoR)
Transition from an echinocandin to
ﬂuconazole for non-neutropenic patients who
have isolates likely to be susceptible to
ﬂuconazole A I
5-Fu: 5-ﬂuorocytosine, ABCD: amphotericin B colloidal dispersion, ABLC: amphotericin B lipid complex, AmB-d: amphotericin B deoxycholate, CVC: central venous catheter,
L-AmB: liposomal amphotericin B, NR: no recommendation, PICC: peripheral inserted central catheter, SoR: strength of recommendation.
aD III, by concomitant nephrotoxic drug and E III by renal impairment.
bRather as step-down therapy.
cLess critically ill patients, no azole exposure.
dNot in severely ill patients or in patients with previous azole prophylaxis.
eNot in patients with previous azole prophylaxis.
fNot all experts agreed, SoR results from a majority vote.
gMay be better than echinocandins against C. parapsilosis.
hAlternative if there is intolerance to or limited availability of other antifungals, transition to ﬂuconazole if the patient is stable and sensible isolates recommended (A I).
iLess critically ill patients, no recent azole exposure, step-down from echinocandins recommended if sensible species and patient stable (A II).
jConsideration given to a loading-dose of 25 mg/kg.
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catheter retention (CII). This is also the only group that
proposes recommendations for the use of colony-stimulating
factors (granulocyte colony-stimulating factor), with a weak
recommendation (CIII), and granulocyte infusion, which might
be an option in desperate cases (CIII).
Candidaemia/invasive candidiasis in non-neutropenic patients
In its guideline for patients without neutropenia, the ESCMID
provides a strong recommendation (AI) for the use of all
echinocandins in comparison with the lipid formulation of
amphotericin B (BI) and voriconazole (BI), whereas the ECIL
and the IDSA provide a strong recommendation for the use of
these alternatives. A main difference is that the ESCMID
guideline does not consider ﬂuconazole to be an agent for
ﬁrst-line therapy any more (CI), but rather as an oral step-down
therapy option in cases of good response to treatment, owing to
its limited spectrum (concerns regarding resistance) and infe-
riority in a randomized study vs. anidulafungin [12,15]. The
ESCMID document states that ﬂuconazole might be an option
for C. parapsilosis infections because of uncertainty about MICs.
Diagnostic procedures
Only the ECIL in its 2009 update and the ESCMID in 2012
made recommendations for the diagnosis of invasive candidi-
asis and candidaemia [2,11,13]. Conventional diagnostic pro-
cedures, such as microscopic examination, sample and blood
culture, and identiﬁcation to the species level, are standardized
and form part of daily clinical practice, but important details
were summarized. There was a need for recommendations
concerning the new non-culture-based techniques. Regarding
its other recommendations, the ECIL group limited its analysis
to the setting of patients with haematological malignancies and
HSCT recipients. Nevertheless, their conclusions are very
similar. The ESCMID moderately recommended the use of the
b-D-glucan assay in the diagnosis of invasive candidiasis,
candidaemia, and chronic disseminated candidiasis, and the
use of mannan/anti-mannan assays in the diagnosis of the two
latter conditions, but not for invasive candidiasis, for both
neutropenic and intensive-care unit patients. The ECIL also
moderately supports these tests, with a lower strength of
recommendation for the mannan/anti-mannan assay in candi-
daemia (CII). Moreover, the ESCMID suggests the use of serial
determination for the b-D-glucan assay, and emphasizes its
utility for ruling out infections.
Invasive aspergillosis
Guidelines on the management of invasive aspergillosis have
proﬁted from data from randomized trials with a high quality of
evidence. Thus, the two international guidelines proposed by the
IDSA in 2000 and updated in 2009 (9) and those of the ECIL
group published in 2005 and updated three times up to 2009 are
very similar for neutropenic patients and HSCT recipients [10].
The ESCMID is in the process of developing a guideline on this
topic.
Ubiquitously, voriconazole 6 mg/kg twice-daily and then
4 mg/kg twice-daily is the treatment of choice, supported by
several randomized studies, with a strong recommendation (AI)
in both guidelines. The ECIL speciﬁes that therapy should begin
with the intravenous form of voriconazole, owing to insufﬁcient
pharmacokinetic data supporting oral therapy (oral initiation
graded CIII). The IDSA recommends beginning therapy with the
parenteral formulation for seriously ill patients (AIII). Neither
gives any recommendation for the duration of the parenteral
administration or the overall duration of the therapy. The
recommendations for diagnosis strategy, indication for surgery,
adjuvant treatment with colony-stimulating factors, manage-
ment of immunosuppression and corticosteroid therapy also
appear to be very similar.
Mucormycosis
Despitemucormycosis being the thirdmost common type of IFI,
there has been, until recently, a lack of recommendations on
diagnosis and the best management. The data on the manage-
ment of these infections are scarce, and consist mainly of case
series and experimental studies. On the basis of this literature,
the ECIL made recommendations in 2009 [12] and the ESCMID
in 2013 [7]. Their conclusions are very similar concerning
diagnostic procedures, ﬁrst-line and salvage therapy, and
adjunctive treatment, in particular the recommendation against
the use of the iron chelator deferasirox and the scarcity of data in
favour of hyperbaric oxygen, and both guidelines emphasize the
importance of surgery in synergy with antifungal therapy and
the control of underlying conditions (e.g. neutropenia and
diabetes). It is important to note here that there is some overlap
of authors between ECIL and ESCMID guideline but basically for
patients with haematological malignancies. Only one point
differs signiﬁcantly between the two documents: the ECIL
considers that posaconazole cannot be recommended for
ﬁrst-line therapy (CIII), whereas the ESCMID considers posa-
conazole 200 mg four times daily or 400 mg twice-daily as a
therapy option, albeit with a weaker strength of recommenda-
tion than for liposomal amphotericin B (BII). This difference in
the strength of recommendations is explained mainly by two
studies assessing the use of posaconazole as ﬁrst-line therapy,
which were published after the ECIL guidelines [16,17].
Finally, we note that the ESCMID discourages the use of
amphotericin B deoxycholate, which is consistent with the
discussions that took place regarding the management of
candidiasis in adults [1,7]. Some items remain unresolved in
both guidelines, in particular the lack of a clear duration or
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therapeutic endpoint, but this is not too surprising since
published data on this matter is rare.
Discussion
The IDSA, ECIL and ESCMID aim at providing evidence-based
international guidelines for the diagnosis and treatment of IFIs.
The clinical recommendations from the expert panels from
these three organizations (two scientiﬁc societies [ESCMID
and IDSA] and one working group [ECIL]) are, in important
respects, consistent, and the fact that their conclusions are
similar enhances their reliability. Although the limited number
of experts and the overlap of authors temper this observation
for the mucormycosis guidelines. A major difference is the
position of the ESCMID experts on the use of amphotericin B
deoxycholate in adults. Their ﬁnal decision is based on a
balance between the accrued toxicity without additional
beneﬁts and the cost incurred by the use of alternative agents
that they feel to be acceptable, at least in Europe. They further
emphasize that the cost-effectiveness of the different thera-
peutic and diagnostic strategies are difﬁcult to assess, because
of the diversity of reimbursement systems in Europe, and that
their guidelines should also be easily adapted to local clinical
practice, with due respect to the local fungal epidemiology and
economic considerations. This also applies to the strong
recommendation on the use of echinocandins over ﬂuconazole
in the ﬁrst-line therapy of candidaemia.
Another important issue is that the grading systems are not
comparable. The ECIL chose to modify its grading system
during the last update of its guideline, which is now identical to
the IDSA’s. This makes comparison between the most recent
recommendations of the ECIL and the IDSA easier, but may
make them more difﬁcult to understand and difﬁcult to use in
daily clinical practice. On the other hand, the ESCMID tries to
emphasize this aspect in the composition of their guideline by
deﬁning clear patient groups, and precise interventions and
intentions for each recommendation, and using a more deﬁnite
grading system. The ESCMID “strength of recommendation”
system is the only one proposing the need for further research
if a grade C is applied to further improve the scientiﬁc grounds
for a given intervention [1].
Some studies have tried to assess adherence to the interna-
tional recommendations and its consequences. In their retro-
spective monocentre study, Nivoix et al. [18] evaluated the
adherence to the recommendations from the ECIL and the IDSA
for 199 antifungal treatments in 133 adults, and found a low rate
of appropriate prescription (34%). The 12-week survival rate
was lower in the group of patients receiving inappropriate or
debatable treatment (70% vs. 81%), but not signiﬁcantly (p 0.24).
The very low rate of adherence to the guidelines in this study
could be attributable to the very stringent criteria deﬁning
‘appropriate’ treatment. Another study, from Patel et al. [19],
assessed not only the choice and dosage of antifungal therapy but
also the global adequacy of the management of 199 patients with
candidaemia with regard to the recommendations from the
IDSA. The therapy was consistent with the guidelines in 76% of
patients, and deviation from these recommendations was
associated with increased mortality (24% vs. 57%, p 0.003). In
a retrospective multicentre study, Pagano et al. [20] observed
55% adherence to IDSA guidelines and 28% adherence to ECIL
guidelines in 136 patients with acute leukaemia and proven or
probable invasive aspergillosis. The ﬁrst-line therapy response
rate was signiﬁcantly better in the group with adherence to the
IDSA (71%) and the ECIL (84%) guidelines than in the remaining
patients (respectively, 59% and 62%), although no difference
could be seen regarding the rate of survival at 120 days. It is
important to note that all of these studies took only the IDSA
and ECIL guidelines into account. The ESCMID guidelines have
not yet been assessed.
These results support the utility of international updated
guidelines for the management of fungal infections but, at the
same time, emphasize the low compliance rate and the need to
enhance their acceptance and usage in daily practice. These
results support the utility of international updated guidelines
for the management of fungal infections but in the same time
emphasize the low compliance rate and the need to enhance
their acceptance and usage in the daily practice. The reasons
underlying the lack of compliance to guidelines are multi-
factorial [21] but the adaptation of international structural
guidelines to the local level, with integration of prescribers into
the process, is likely to enhance their diffusion and acceptance
rate. Another argument to the adaptation to the local setting is
the important geographical variations in the epidemiology. In
this, the role of the specialist in infectious disease seems to be
pivotal and the inclusion of antifungal stewardship in the
antimicrobial stewardship programs the keys to an optimisa-
tion of the management of fungal diseases [22]. To this respect,
the need of several international guidelines in different areas of
the world might not be that questionable.
In the near future further collaboration might ﬁll the gap for
streamlined recommendations. It could resolve the problem of
the most debated and inconsistent points and harmonize the
grading system for the strength of recommendation and quality
of evidence, that are issues in the adherence due to the
difﬁculty of comparing the current guidelines. The GRADE
working group could be a possible solution. When focussing
on those differences a real international guideline comes within
the reach of a possibility. The main obstacles in the
development of such a guideline remain, as stated in the
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introduction of ESCMID recommendations, the need to create
a useful and comprehensive framework that could be utilized
in local modiﬁed operating procedures by physicians and the
difﬁculty of balancing the economic considerations and
complexity of national reimbursement system with recom-
mendations based on sound evidences from controlled clinical
trials. While covering all aspects and opinions an international
guideline for all will remain a challenge.
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